A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder
Authors:
- David S. BaldwinDBDavid S. Baldwin
- James A. CooperJCJames A. Cooper
- Anna K.T. HuusomAHAnna K.T. Huusom
- Ian HindmarchIHIan Hindmarch
- 1 May 2006
- journal article
- research article
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 21 (3) , 159-169
Abstract
This multinational, randomized, double-blind, flexible-dose study evaluated the short- and long-term antidepressant tolerability and efficacy of escitalopram and paroxetine. Tolerability was assessed by monitoring adverse events throughout the study, and discontinuation events during brief treatment interruption and tapered withdrawal. Discontinuation-emergent effects were evaluated in two separate double-blind periods. First, to mimic the consequences of non-compliance, patients were randomized to one of two treatment interruption periods (placebo-substitution for 3-5 days). Second, patients were randomized to a 1-2-week tapered withdrawal period randomly scheduled between weeks 28 and 31. The pre-specified primary efficacy endpoint was the mean change from baseline in total Montgomery-Asberg Depression Rating Scale (MADRS) score at week 8, using the principle of last observation carried forward. A total of 323 patients entered 8 weeks of double-blind treatment and received at least one flexible dose of escitalopram (10-20 mg/day) or paroxetine (20-40 mg/day). Patients who demonstrated evidence of a significant clinical improvement (Clinical Global Impression-Improvement of 1 or 2) at week 8 entered a 19-week, double-blind maintenance period during which they were treated with the same dose they received at week 8, followed by a 1-2-week tapered withdrawal period. A total of 89 patients (28%) withdrew during the study; significantly (Por=30), escitalopram was superior (P<0.05) to paroxetine at week 27 (end of maintenance treatment). There was a high prevalence of sexual dysfunction at baseline: the mean Arizona Sexual Experience Scale (ASEX) score was approximately 20 points in both treatment groups. Mean total ASEX scores increased slightly above baseline values during the acute period and declined slightly below baseline values towards the end of the maintenance period. During taper and cessation of treatment, patients in the paroxetine group demonstrated significantly more discontinuation symptoms relative to escitalopram based on the Discontinuation Emergent Signs and Symptoms scores.Keywords
This publication has 25 references indexed in Scilit:
- A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorderCurrent Medical Research and Opinion, 2005
- Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety reviewBMJ, 2005
- Comparison of escitalopram and citalopram efficacy: A meta-analysisInternational Journal of Psychiatry in Clinical Practice, 2003
- Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary careInternational Clinical Psychopharmacology, 2003
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance Treatment of Major Depressive Disorder and Treatment of Chronic Depressive Disorders and Subthreshold DepressionsThe World Journal of Biological Psychiatry, 2002
- Affective Disorders and Suicide Risk: A ReexaminationAmerican Journal of Psychiatry, 2000
- Interruption of selective serotonin reuptake inhibitor treatmentThe British Journal of Psychiatry, 2000
- Clinically relevant effect sizes in depressionEuropean Neuropsychopharmacology, 1994
- Placebo-controlled efficacy of antidepressants in continuation treatmentInternational Clinical Psychopharmacology, 1994
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979